Last reviewed 2026-04-23 · How we verify

DA5221-B2

DA5221-B2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.

DA5221-B2 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.

At a glance

Mechanism of action

By simultaneously activating GLP-1 and GIP receptors, DA5221-B2 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety, leading to improved blood glucose levels and reduced body weight. This dual-agonist approach may provide superior efficacy compared to single GLP-1 agonists in managing type 2 diabetes and obesity.

Approved indications

• Type 2 diabetes mellitus
• Obesity or weight management

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal disorders

Key clinical trials

• Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DA5221-B2 CI brief — competitive landscape report
• DA5221-B2 updates RSS · CI watch RSS
• Dong-A ST Co., Ltd. portfolio CI